Antibody response of HIV-infected patients to latent, cerebral and recently acquired toxoplasmosis
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Retroviral Agents therapeutic use MeSH
- Child MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- HIV Infections complications drug therapy MeSH
- Immunoglobulin G blood MeSH
- Immunoglobulin M blood MeSH
- Complement Fixation Tests MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Adolescent MeSH
- Toxoplasmosis, Cerebral complications diagnosis epidemiology immunology MeSH
- Predictive Value of Tests MeSH
- Child, Preschool MeSH
- Antibodies, Protozoan blood MeSH
- Aged MeSH
- Toxoplasma isolation & purification MeSH
- Toxoplasmosis complications diagnosis epidemiology immunology MeSH
- Animals MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Retroviral Agents MeSH
- Immunoglobulin G MeSH
- Immunoglobulin M MeSH
- Antibodies, Protozoan MeSH
The aim of this longitudinal study with 626 HIV-infected patients was to evaluate the capability of serological tests in diagnosing the presence of Toxoplasma gondii infection in HIV-infected patients, as well as the potential impact of various treatment regimes on serological results. Low IgG antibody levels and stable or declining titres predominated. IgM positivity occurred in ten patients (one seroconversion, seven latent, two cerebral toxoplasmosis). Complement fixation test (CFT) titres >or=1:32 imply that the relative risk of cerebral toxoplasmosis is 6.84 (95% confidence interval [CI] 1.44-32.5) but with a predictive value of only 14.0% (95% CI 5.3-27.9). Values of specific antibodies are not biassed by antiretroviral treatment and/or prophylaxis for toxoplasmosis, and the detection of specific antibodies is very useful in the identification of T. gondii infection in the HIV-infected population, but the role of serology in predicting the clinical manifestation of T. gondii infection is limited.
See more in PubMed
Clin Microbiol Infect. 2007 Jan;13(1):40-7 PubMed
Infection. 1998 Jan-Feb;26(1):20-5 PubMed
Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):591-5 PubMed
AIDS. 1991 Nov;5(11):1363-5 PubMed
AIDS. 1996 Nov;10(13):1521-7 PubMed
Clin Infect Dis. 1999 Mar;28(3):575-81 PubMed
Clin Infect Dis. 1992 Aug;15(2):211-22 PubMed
Acta Neurol Scand. 1999 Sep;100(3):178-84 PubMed
J Acquir Immune Defic Syndr (1988). 1993 Apr;6(4):414-8 PubMed
J Eukaryot Microbiol. 2006;53 Suppl 1:S160-1 PubMed
J Clin Microbiol. 2005 Oct;43(10):5044-7 PubMed
The Effect of Latent Toxoplasma gondii Infection on the Immune Response in HIV-Infected Patients
